ClinicalTrials.gg
WithdrawnNCT06881888Updated Oct 13, 2026

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

A Phase 1 interventional study of Octreotide (drug) and Placebo in Diabetic Macular Edema, sponsored by University of Alabama at Birmingham. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of Alabama at Birmingham · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Project terminated due to loss of sponsor funding following the dissolution of AMD Opti.
Updated Oct 13, 2026Now WithdrawnPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
190th of 196
0 · median 72
Started
2026
with 18 others
Phase 1
29 of 267
4 open now
Registered
242nd of 267
by date
Lead sponsor
7 of 267
University of Alabama at Birmingham

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 190th largest by enrollment of the 196 interventional ones that give a count, is one of 19 that started in 2026, is one of 29 in phase 1, and was the 242nd registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

Treatment of diabetic retinopathy (DR) and diabetic macula edema has included panretinal photocoagulation and intra ocular injections of anti-vascular endothelial growth factors (anti-VEGF) agents and steroids. Anti-VEGF therapy is currently the first-line treatment for proliferative diabetic retinopathies; however, this approach is ineffective in more than 30% of patients with diabetic retinal complications. Available evidence shows that subcutaneous (under the skin) injection of octreotide, a somatostatin analog, has potential therapeutic benefits in proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME). This study thus seeks to determine the efficacy and safety of intranasal DDM-octreotide in the treatment of diabetic macula edema in individuals that are considered to be refractory to the current therapeutic options.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • Diabetic Macular Edema
  • Intranasal Octreotide
  • Octreotide
  • Diabetic Retinopathy
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range 18-90
  2. Clinical diagnosis of diabetic retinopathy with diabetic macular edema (defined as CST greater than 250 and presence of microglia/macrophages on OCT) with a visual acuity between 20/32 and 20/200.
  3. Written is provided.
  4. Males and females
  5. Routine laboratory study results with , and/or alanine aminotransferase, and creatinine within normal limits.

Exclusion criteria

Exclusion Criteria:

  1. History of difficult to control diabetes or hypertension
  2. Eyes receiving laser photocoagulation in the last 6 months or intravitreous treatment for diabetic macular edema in the past 3 months.
  3. Eye having undergone YAG capsulotomy in the last 3 months.
  4. Having other ocular surgeries in the last 6 months (examples include but not limited to cataract surgery, scleral buckle, trabeculectomies, etc.).
  5. All women of must have a negative urine pregnancy test at the Screening Visit and throughout the study. Sexually active women participating in the study must use a medically acceptable form of .
  6. Chronic infectious disease (e.g. , )
  7. Positive urine β-hCG test day of visit or a serum beta-HCG test within 48 hours prior to the administration of intranasal octreotide.
  8. Other ocular diseases or fundus diseases
  9. Patients with a history of intolerance or to octreotide or use of octreotide in the preceding 2 months.
  10. Currently taking an anti-inflammatory medication (e.g. anti-inflammatory agents, or other immune modulating medications);
  11. Use of cyclooxygenase-2 (COX-2) inhibitors for \< 6 months prior to study entry or dose changes after study entry. Limited as-needed use is permitted prior to study entry but not during the study.
  12. Use of statins that cross the blood brain barrier such as atorvastatin will not be permitted during the study as they have been shown to reduce levels of pro-inflammatory cytokines.
  13. Any degree of hepatic or renal insufficiency that in the Investigator's judgement would pose a safety risk for treatment with octreotide.
  14. Patients who based on history or mental status examination have a significant risk of committing suicide, or who are homicidal or violent and who are in the Investigator's opinion in significant imminent risk of hurting others.
  15. Patients who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial.
  16. Patients with a current known infection or who are acutely ill.
  17. Patients with an disease (i.e., Lupus, Rheumatoid Arthritis).
  18. Patients with thyroid disorders unless euthyroid at screening.
  19. Patients with cancer not in remission.
  20. Inability to tolerate or intranasal administration of investigated drug and experiences severe irritation or sneezing.
  21. Inability to attend scheduled study visits, plans for family relocation during the study, or any other criteria that the investigator may determine to be associated with inability to complete the study.
  22. Limited mental capacity rendering the subject unable to provide written or comply with evaluation procedures.
  23. History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols.
  24. Use of any drug within 30 days prior to the baseline visit.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Octreotide Arm

    Participants will receive the investigational drug, DDM-Octreotide, and administering intranasally in one nostril three times a day.

    Drug: Octreotide (drug)

  • Placebo comparator
    Control Group

    The control group will receive a placebo nasal spray without the active ingredient, DDM-octreotide, and administering intranasally in one nostril three times a day.

    Drug: Placebo

Interventions

  • DrugOctreotideStudies of OctreotideOctreotide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will administer the DDM-octreotide nasal spray without priming in one nostril three times a day.

    Also known as: Octreotide and 1-O-n-Dodecyl-b-D-Maltoyranoside (DDM) (Intravail®)

  • DrugPlacebo

    Participants will administer the placebo nasal spray without priming in one nostril three times a day.

06

What researchers measure

Primary outcomes

  1. Change in macular central subfield thickness

    Participants will have an optical coherence tomography at each visit that will measure macular central subfield thickness. Measuring the change at their baseline appointment and each additional study visit.

    Time frame: Up to one month.

  2. Change in best corrected visual acuity

    Each participant will have best corrected visual acuity measured by Early Treatment of Diabetic Retinopathy study (ETDRS) chart. Enter the full scale.

    Time frame: Up to one month.

  3. Change in microglia on retinal surface

    Each participant will have an optical coherence tomography angiography scan measuring the quantity of microglia on the retinal surface.

    Time frame: Up to one month

  4. Changes in retinal peripheral capillary free zone

    Each participant will have optical coherence tomography angiography and measure differences in retinal peripheral capillary free zone.

    Time frame: up to one month

  5. Changes in retinal foveal avascular zone

    Each participant will have optical coherence tomography angiography and measure differences in retinal foveal avascular zone.

    Time frame: up to one month

  6. Changes in retinal capillary density

    Each participant will have optical coherence tomography angiography and measure differences in retinal capillary density.

    Time frame: up to one month

  7. Changes in retinal non-perfusion zones

    Each participant will have optical coherence tomography angiography and measure differences in retinal non-perfusion zones.

    Time frame: up to one month

Secondary outcomes

  1. Changes in serum insulin like growth factor -1 (IGF-1) levels

    Each participant will have serum IGF-1 levels measured.

    Time frame: up to one month.

07

Study locations

1 site
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35243, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Aug 2026.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2027 → Oct 2026 and completion Dec 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 18, 2025
StartEst.
Aug 31, 2026
Primary completionActual
Oct 8, 2026was Dec 2027
CompletionActual
Oct 8, 2026was Dec 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Project terminated due to loss of sponsor funding following the dissolution of AMD Opti.
changed Oct 13, 2026
Primary completion
Dec 2027→Oct 8, 2026 (actual)
Oct 13, 2026
Study completion
Dec 2027→Oct 8, 2026 (actual)
Oct 13, 2026
Enrollment
60 (estimated)→0 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Withdrawn
    Why stopped Project terminated due to loss of sponsor funding following the dissolution of AMD Opti.
    Primary completion Dec 2027→Oct 8, 2026 (now actual)
    Study completion Dec 2027→Oct 8, 2026 (now actual)
    Enrollment 60 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06881888
Responsible party
Maria Grant (Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Mar 18, 2025
Start date
Aug 31, 2026 (estimated)
Primary completion
Oct 8, 2026
Completion
Oct 8, 2026
Last update
Oct 13, 2026

Study contacts

Maria Grant, MD, FARVO
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion